Video
1 Apr 2025

CARBOGEN AMCIS Secures GMP Certification

MP4 74.2 MB

CARBOGEN AMCIS is pleased to announce the successful completion of the first inspection by the French regulatory authority, ANSM (Agence nationale de sécurité du médicament et des produits de santé), at its state-of-the-art sterile drug product manufacturing site in Saint-Beauzire, France.

CARBOGEN AMCIS has been granted a GMP certificate for the Saint-Beauzire facility, marking a significant milestone in the site's successful start-up. The certificate allows for the manufacture and release of clinical and commercial sterile drug products. The site received authorization from the ANSM to manufacture, test and release drug products from February 2023 and since then has been working under this authorization with the first clinical batch released in January 2024.

Content provided by our supplier

CARBOGEN AMCIS

  • Country/Region:
    Switzerland
  • On CPHI since:
    2015
  • Certificates:
    1
  • Employees:
    1000 - 4999
Company types
CMO/CDMO
Contract Service
Primary activities
API Producer
Clinical Research
Contract Manufacturer
Contract Research Organisation

Other Content from CARBOGEN AMCIS (3)

  • News CARBOGEN AMCIS Secures GMP Certification After Successful ANSM Inspection for its Aseptic Drug Product Manufacturing Site

    CARBOGEN AMCIS is pleased to announce the successful completion of the first inspection by the French regulatory authority, ANSM (Agence nationale de sécurité du médicament et des produits de santé), at its state-of-the-art sterile drug product manufacturing site in Saint-Beauzire, France.

    The inspection, conducted from January, 20th to January, 24th, follows the site’s opening in February 2023. This is the first inspection of a routine process by ANSM to ensure compliance with Good Manufacturing Practices (GMP). As a result, CARBOGEN AMCIS has been granted a GMP certificate for the Saint-Beauzire, France.
  • News Swissmedic Inspection Success Highlights Excellence at CARBOGEN AMCIS Vionnaz Site

    BUBENDORF, Switzerland (January 13, 2025) — Switzerland-based CARBOGEN AMCIS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce the successful completion of a Swissmedic inspection of its Vionnaz facility, reaffirming the site’s compliance with high regulatory standards.
  • Brochure Company Profile

    Dowload our brochure and learn more about our offers. 
    Drug development to Commercialization services for pharmaceutical and biopharmaceutical industries at all stages of drug development

    Your CDMO from Drug Substance to Drug Product